
- /
- Supported exchanges
- / XETRA
Novo Nordisk A/S (NOV XETRA) stock market data APIs
Novo Nordisk A/S Financial Data Overview
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Novo Nordisk A/S data using free add-ons & libraries
Get Novo Nordisk A/S Fundamental Data
Novo Nordisk A/S Fundamental data includes:
- Net Revenue: 270 583 M
- EBITDA: 127 401 M
- Earnings Per Share: 3
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-02-05
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Novo Nordisk A/S News

Is It Worth Investing in Novo Nordisk (NVO) Based on Wall Street's Bullish Views?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often ...


Novo Nordisk A/S (NVO): Among Ken Fisher’s Top High Growth Stock Picks
We recently compiled a list of the Billionaire Ken Fisher's Top 10 High Growth Stock Picks.In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other st...

IBD 50 Stock Hims & Hers Faces Backlash Over Provocative Super Bowl Ad
Hims stock surged into a profit-taking zone Friday after facing backlash over its provocative Super Bowl ad that criticized the makers of approved weight-loss drugs. On Friday, Sen. Richard Durbin (D-...

Pharma Stock Roundup: PFE, LLY, NVO, LLY and AZN's Q4 Earnings Update
This week was loaded with earnings releases of many large drugmakers. Novo Nordisk NVO, Merck MRK, Pfizer PFE, Eli Lilly LLY, AstraZeneca AZN and AbbVie announced their fourth-quarter and full-year 20...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.